Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill aims to supercharge weight loss in obesity

NCT ID NCT07505303

Disease control Sponsor: Eccogene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2a trial tests whether adding an oral drug called ECC4703 to the weekly injection semaglutide helps adults with obesity lose more weight and reduce liver fat. About 151 participants will take either ECC4703 or a placebo alongside semaglutide for 20 weeks. The study is active but no longer recruiting, and results will show if the combination is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ECC4703 (oral drug) added to semaglutide (injectable drug)
What this could lead to
If it works, this could lead to a more effective weight-loss treatment by combining two drugs, potentially helping people with obesity lose more weight and reduce liver fat.
What could go wrong
This is an early Phase 2a trial with only 151 people, so results may not apply to everyone. The drug combination could cause side effects, and it's not yet known if it works better than semaglutide alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

151 people

The number who actually took part.

Started

Mar 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Capable of providing written informed consent and complying with all trial procedures. 2. Willing to comply with contraception requirements (as applicable to males and females of childbearing potential). 3. Obese with BMI ≥30 kg/m\^2 and stable body weight within 6 months prior to screening. 4. HbA1c ≤6.5%. 5. Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 (per CKD-EPI 2021 formula). 6. If participant consents to enter the imaging substudy, has liver fat content by MRI-PDFF \>8% at baseline (Week 9). Exclusion Criteria: 1. History or current diagnosis of type 1 or type 2 diabetes mellitus. 2. Weight change \>5% of total body weight within 6 months prior to screening or planned initiation of a weight loss program or use of weight-altering medication. 3. Obesity induced by endocrine disorders such as Cushing's syndrome or monogenic or syndromic obesity such as Prader-Willi syndrome. 4. Use of GLP-1 agonist treatment within the last 6 months prior to screening. 5. History or current evidence of a pituitary disorder. 6. Have current treatment with or history (within 3 months prior to screening) of treatment with medications that may cause significant weight gain. 7. ALT or AST \>1.5×ULN, or ALP \>1.5×ULN at screening. 8. Documented evidence or clinical signs/symptoms of advanced liver disease including liver cirrhosis, portal hypertension, or hepatic decompensation. 9. History of significant alcohol consumption for \>3 consecutive months within a year prior to screening. 10. Current or past therapy with THR-β agonists (eg, resmetirom). 11. Active untreated hyperthyroidism or hyperthyroidism currently treated with antithyroid medications including methimazole or propylthiouracil. 12. Clinically significant thyroid dysfunction including uncontrolled hypothyroidism or hyperthyroidism. 13. History of bariatric surgery, fitting of a weight loss device, or intestinal bypass surgery within 5 years prior to screening. 14. History of major surgery within 8 weeks prior to screening. 15. Clinically relevant acute or chronic medical condition or unstable disease of the cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immune or dermatologic system.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adult obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adult obesity Weight management

Contacts and locations

Locations

  • AES - DRS - Optimal Research Florida - Melbourne

    Melbourne, Florida, 32934, United States

  • AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis

    Richfield, Minnesota, 55423, United States

  • AES - DRS - Synexus Clinical Research US, Inc. - San Antonio

    San Antonio, Texas, 78229, United States

  • Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS

    Anaheim, California, 92081, United States

  • Atlanta Center for Medical Research - CenExel ACMR - PPDS

    Atlanta, Georgia, 30331, United States

  • Central Research Associates - Flourish - PPDS

    Birmingham, Alabama, 35205, United States

  • Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS

    Los Alamitos, California, 90720, United States

  • Flourish Research - San Antonio - PPDS

    San Antonio, Texas, 78229, United States

  • ForCare Clinical Research - CenExel FCR - PPDS

    Tampa, Florida, 33613, United States

  • Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS

    Omaha, Nebraska, 68134, United States

  • Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS

    Cincinnati, Ohio, 45246, United States

  • Velocity Clinical Research - Dallas - PPDS

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research - Durham - PPDS

    Durham, North Carolina, 27701, United States

  • Velocity Clinical Research - Providence - PPDS

    East Greenwich, Rhode Island, 02818, United States

  • iResearch Atlanta - CenExel - PPDS

    Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.